Chronic Spontaneous Urticaria Market

DelveInsight’s ‘Chronic Spontaneous Urticaria Market Insight, Epidemiology and Market Forecast—2032’ report deliver an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Chronic Spontaneous Urticaria market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chronic Spontaneous Urticaria symptoms, market size from 2019 to 2032 segmented by seven major markets. The report also covers current Chronic Spontaneous Urticaria symptoms, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Chronic Spontaneous Urticaria Understanding and Treatment Algorithm

Chronic Spontaneous Urticaria Overview

Chronic Urticaria is a debilitating disease characterized by itching and hives with or without angioedema, lasting for more than 6 weeks. Chronic Urticaria might be triggered due to stimuli such as stroking or scratching the skin, exercise, emotional upset (cholinergic urticaria), cold, heat, pressure, sunlight (solar urticaria), contact with water or various chemicals (contact urticaria), or vibration. Urticaria induced, thus, is known as chronic induced urticaria (CIndU). However, more commonly chronic urticaria is endogenous and independent of any external causes. This urticaria is known as chronic spontaneous urticaria (CSU).

 

Historically, the term chronic “idiopathic” urticaria was used for years as CSU’s underlying cause remained unknown. This remains true for a major subpopulation of patients. However, it is now understood that in about 40–45% of Chronic Spontaneous Urticaria patients, autoimmunity is the cause. Urticaria is common; it is estimated that 25% of the population suffers from it at one point in their life. At any single time, 0.5–1% of the population suffer from chronic urticaria. Two-thirds of chronic urticaria cases are spontaneous, with females twice as likely to be affected as males. 

 

Diagnosis rates in these patients are lower as patients are likely to use anti-inflammatory OTC products for self-treatment. Various guidelines for treatment such as EAACI/Ga2LEN/EDF/WAO and AAAAI/ACAAI are available for the treatment of Chronic Spontaneous Urticaria. The mainstay of initial treatment remains modern second-generation antihistamines. The frontline antihistamine treatment is effective in ~50% of Chronic Spontaneous Urticaria patients. Currently used treatments are Xolair Prescription, antihistamine, oral corticosteroids, leukotriene receptor antagonists, immunosuppressive agents.

 

There are a large number of alternative treatments for antihistamines refractory patients, such as corticosteroids, leukotriene antagonists, antidepressants, etc. but the evidence of efficacy for most is weak. In 2014, Roche and Novartis’ Xolair (Omalizumab) an anti-IgE monoclonal antibody, became only other therapy, apart from antihistamines to have FDA approval in the treatment of Chronic Spontaneous Urticaria refractory to H1 antihistamine treatment.

 

Currently, there are a lot of clinical trials ongoing in Chronic Spontaneous Urticaria. Novartis’ Ligelizumab, a monoclonal anti-IgE antibody has shown superior efficacy over Omalizumab in phase2b and is currently being evaluated in phase 3 trial. Sanofi and Regeneron’s Dupixent (dupilumab), already approved in atopic dermatitis is being evaluated in phase III for Chronic Spontaneous Urticaria. Various other emerging drugs in various phases of trials are Rilzabrutinib (Sanofi/Regeneron), Remibrutinib (Novartis), Benralizumab (AstraZeneca), Fenebrutinib (Genentech), KPL-716 (Kiniksa Pharma), UB-221 (United BioPharma),  Mepolizumab (GlaxoSmithKline), AK002 (Allakos). 

 

However, there are still few unmet needs in the understanding of disease etiology in cases where autoimmunity is ruled out. Quality of life is severely impacted in Chronic Spontaneous Urticaria patients due to unpredictability of attacks, fatigue caused by treatment side effects, and cosmetic disfigurement. Patients with Chronic Spontaneous Urticaria often exhibit psychiatric comorbidities. Chronic Spontaneous Urticaria also has a large direct and indirect economic impact due to increased healthcare cost because of continued medication to control symptoms, and frequent, often unanticipated healthcare visits.

 

Chronic Spontaneous Urticaria Diagnosis and Treatment 

It covers the details of conventional and current medical therapies and diagnosis available in the Chronic Spontaneous Urticaria market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, the Europe, and Japan. 

 

The DelveInsight Chronic Spontaneous Urticaria market report gives a thorough understanding of Chronic Spontaneous Urticaria symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Chronic Spontaneous Urticaria algorithms and treatment guidelines in the US, the Europe, and Japan. 

Chronic Spontaneous Urticaria Epidemiology 

The epidemiology division’s Chronic Spontaneous Urticaria symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Spontaneous Urticaria epidemiology segmented as the Total Prevalent cases of Chronic Spontaneous Urticaria, Gender-specific Cases of Chronic Spontaneous Urticaria, and Age-specific cases of Chronic Spontaneous Urticaria. The report includes the Chronic Spontaneous Urticaria scenario in 7MM, covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032. 

Country Wise- Chronic Spontaneous Urticaria Epidemiology 

The epidemiology segment also provides the Chronic Spontaneous Urticaria epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

 

The total 7MM prevalent population of Chronic Spontaneous Urticaria were 1,848,622 cases in 2021

Chronic Spontaneous Urticaria Drug Chapters 

The drug chapter segment of the Chronic Spontaneous Urticaria report encloses the detailed analysis of Chronic Spontaneous Urticaria marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Chronic Spontaneous Urticaria clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Chronic Spontaneous Urticaria Emerging Drugs 

 

Ligelizumab (Novartis Pharmaceuticals)

Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody being developed by Novartis Pharmaceuticals. It is thought to work by blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CSU. It has previously shown dose-dependent and time-dependent suppression of free IgE, basophil FcεRI, basophil surface IgE, and skin-prick test responses to an allergen that was superior in extent and duration to that observed with omalizumab and aims to become first-choice biologic after antihistamine therapy. 

 

In January 2021, Novartis ligelizumab (QGE031) received FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU). Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines.

Products detail in the report…

Chronic Spontaneous Urticaria Market Outlook

The Chronic Spontaneous Urticaria market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Chronic Spontaneous Urticaria market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology. 

 

This segment gives a thorough detail of Chronic Spontaneous Urticaria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

 

According to DelveInsight, Chronic Spontaneous Urticaria market in the 7MM is expected to change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Chronic Spontaneous Urticaria market in the 7MM. The market size of Chronic Spontaneous Urticaria in the seven major markets was found to be USD 1,315.3 million in 2021. 

 

The United States Market Outlook

This section provides a total of Chronic Spontaneous Urticaria market size and market size by therapies in the United States. 

 

The United States accounts for higher Chronic Spontaneous Urticaria market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. 

 

EU-5 Countries: Market Outlook

The total Chronic Spontaneous Urticaria market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook 

The total Chronic Spontaneous Urticaria market size and market size by therapies in Japan are also mentioned. 

Chronic Spontaneous Urticaria Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Chronic Spontaneous Urticaria market uptake by drugs, patient uptake by therapies, and drug sales. 

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

 

Chronic Spontaneous Urticaria Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Chronic Spontaneous Urticaria key players involved in developing targeted therapeutics. 

 

Major players LOU064 (Remibrutinib) (Novartis Pharmaceuticals), Dupilumab, and others are being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chronic Spontaneous Urticaria emerging therapies.

KOL Views 

To keep up with current market trends, we take KOLs and SME’s opinion working on Chronic Spontaneous Urticaria domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Chronic Spontaneous Urticaria market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs. 

Competitive Intelligence Analysis 

We perform a Competitive and Market Intelligence analysis of the Chronic Spontaneous Urticaria Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Chronic Spontaneous Urticaria explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Chronic Spontaneous Urticaria epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Spontaneous Urticaria provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Spontaneous Urticaria market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chronic Spontaneous Urticaria market

Report Highlights

  • In the coming years, Chronic Spontaneous Urticaria market is set to change due to the rising awareness of the disease, resistant to the current antibiotic regime, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Spontaneous Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic Spontaneous Urticaria. The launch of emerging therapies will significantly impact the Chronic Spontaneous Urticaria market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Spontaneous Urticaria
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Spontaneous Urticaria Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Spontaneous Urticaria Pipeline Analysis
  • Chronic Spontaneous Urticaria Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Spontaneous Urticaria Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Chronic Spontaneous Urticaria Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Spontaneous Urticaria Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Chronic Spontaneous Urticaria (%) distribution in 2022, and how would it look in 2032?
  • What would be the Chronic Spontaneous Urticaria total market Size as well as market Size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the market’s key findings across 7MM, and which country will have the largest Chronic Spontaneous Urticaria market Size during the forecast period (2022–2032)?
  • At what CAGR, the Chronic Spontaneous Urticaria market is expected to grow by 7MM during the forecast period (2022–2032)?
  • What would be the Chronic Spontaneous Urticaria market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Chronic Spontaneous Urticaria market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Chronic Spontaneous Urticaria?
  • What is the historical Chronic Spontaneous Urticaria patient pool in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chronic Spontaneous Urticaria in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Chronic Spontaneous Urticaria?
  • Out of all 7MM countries, which country would have the highest prevalent Chronic Spontaneous Urticaria population during the forecast period (2022–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Chronic Spontaneous Urticaria?
  • What are the current treatment guidelines for treating Chronic Spontaneous Urticaria in the US, the Europe, and Japan?
  • What are the Chronic Spontaneous Urticaria marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chronic Spontaneous Urticaria?
  • How many therapies are developed by each company for the treatment of Chronic Spontaneous Urticaria?
  • How many emerging therapies are in the mid-stage and late development stages to treat Chronic Spontaneous Urticaria?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Spontaneous Urticaria therapies? 
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Chronic Spontaneous Urticaria and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic Spontaneous Urticaria?
  • What are the global historical and forecasted markets of Chronic Spontaneous Urticaria?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Spontaneous Urticaria market
  • To understand the future market competition in the Chronic Spontaneous Urticaria market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Spontaneous Urticaria in the US, the Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Spontaneous Urticaria market
  • To understand the future market competition in the Chronic Spontaneous Urticaria market 

1. Key Insights

2. Report Introduction

3. Chronic Spontaneous Urticaria Market Overview at a Glance

3.1. Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2019

3.2. Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2032

4. Executive Summary of Chronic Spontaneous Urticaria

5. Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Clinical Manifestation

5.7. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Patient Population of Chronic Spontaneous Urticaria

6.3. The United States

6.3.1. Assumption and Rationale

6.3.2. Total Prevalent cases of Chronic Spontaneous Urticaria in the United States

6.3.3. Gender-specific Cases of Chronic Spontaneous Urticaria in the United States

6.3.4. Age-specific cases of Chronic Spontaneous Urticaria in the United States

6.4. EU5

6.4.1. Assumption and Rationale

6.4.2. Total Prevalent cases of Chronic Spontaneous Urticaria in EU-5

6.4.3. Gender-Specific Cases of Chronic Spontaneous Urticaria in EU-5

6.4.4. Age-specific cases of Chronic Spontaneous Urticaria in EU-5

6.5. Japan

6.5.1. Assumption and Rationale

6.5.2. Total Prevalent cases of Chronic Spontaneous Urticaria in Japan

6.5.3. Gender-Specific cases of Chronic Spontaneous Urticaria in Japan

6.5.4. Age-specific cases of Chronic Spontaneous Urticaria in Japan

7. Treatment and Management

7.1. Treatment and Management

7.2. EAACI/GA²LEN/EDF/WAO guideline

8. Patient Journey

9. Marketed Therapies

9.1. XOLAIR: Roche/Novartis

9.1.1. Drug Description

9.1.2. Regulatory Milestones

9.1.3. Other Development Activities

9.1.4. Clinical Development

9.1.4.1. Clinical Trials Information

9.1.5. Safety and Efficacy

9.1.6. Product Profile

10. Emerging Therapies

10.1. Ligelizumab: Novartis Pharmaceuticals

10.1.1. Drug Description

10.1.2. Product Development

10.1.3. Clinical Development

10.1.3.1. Clinical Trials Information

10.1.4. Safety and Efficacy

10.1.5. Product Profile

10.2. LOU064 (Remibrutinib): Novartis Pharmaceuticals

10.2.1. Drug Description

10.2.2. Product Development

10.2.3. Clinical Development

10.2.3.1. Clinical Trials Information

10.2.4. Safety and Efficacy

10.2.5. Product Profile

10.3. Dupilumab: Sanofi Pharmaceutical

10.3.1. Drug Description

10.3.2. Product Development

10.3.3. Clinical Development

10.3.3.1. Clinical Trials Information

10.3.4. Safety and Efficacy

10.3.5. Product Profile

10.4. Rilzabrutinib: Sanofi Pharmaceutical

10.4.1. Drug Description

10.4.2. Product Development

10.4.3. Product Profile

10.5. Fenebrutinib: Genentech

10.5.1. Drug Description

10.5.2. Product Development

10.5.3. Clinical Development

10.5.3.1. Clinical Trials Information

10.5.4. Safety and Efficacy

10.5.5. Product Profile

10.6. Benralizumab: AstraZeneca

10.6.1. Drug Description

10.6.2. Other Developmental Activities

10.6.3. Clinical Development

10.6.3.1. Clinical trials information

10.6.4. Product Profile

10.7. KPL-716: Kiniksa Pharmaceuticals, Ltd

10.7.1. Drug Description

10.7.2. Other Developmental Activities

10.7.3. Clinical Development

10.7.3.1. Clinical Trials Information

10.7.4. Safety and Efficacy

10.7.5. Product Profile

10.8. UB-221: United BioPharma

10.8.1. Drug Description

10.8.2. Other Developmental Activities

10.8.3. Clinical Development

10.8.3.1. Clinical Trials Information

10.8.4. Safety and Efficacy

10.8.5. Product Profile

10.9. Mepolizumab: GlaxoSmithKline

10.9.1. Drug Description

10.9.2. Clinical Development

10.9.2.1. Clinical Trials Information

10.9.3. Product Profile

10.10. AK002: Allakos

10.10.1. Drug Description

10.10.2. Other Developmental Activities

10.10.3. Clinical Development

10.10.3.1. Clinical Trials Information

10.10.4. Safety and Efficacy

10.10.5. Product Profile

11. Dormant Therapies

11.1. LY3454738: Eli Lilly and Company

11.1.1. Drug Description

11.1.2. Other Developmental Activities

11.1.3. Clinical Development

11.1.3.1. Clinical Trials Information

11.1.4. Product Profile

12. Chronic Spontaneous Urticaria: 7 Major Market Analysis

12.1. Key Findings

12.2. Total Market Size of Chronic Spontaneous Urticaria in 7MM

13. Country-wise Market Analysis

13.1. Market Outlook

13.2. United States

13.2.1. Total Market Size of Chronic Spontaneous Urticaria in the United States

13.2.2. Total Market Size of Chronic Spontaneous Urticaria by Therapies in the United States

13.3. EU-5 Countries

13.3.1. Total Market Size of Chronic Spontaneous Urticaria in EU-5

13.3.2. Market Size of Chronic Spontaneous Urticaria by Therapies in EU-5

13.3.3. Japan

13.3.4. Total Market Size of Chronic Spontaneous Urticaria in Japan

13.3.5. Total Market Size of Chronic Spontaneous Urticaria by Therapies in Japan

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Market Access

17.1. Reimbursement

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

List of Table

Table 1: Summary of Chronic Spontaneous Urticaria, Market and Epidemiology (2019–2032)

Table 2: Total Patient Population of Chronic Spontaneous Urticaria in the 7MM (2019–2032)

Table 3: Total Prevalent Cases of Chronic Spontaneous Urticaria in the US (2019–2032)

Table 4: Gender-Specific Cases of Chronic Spontaneous Urticaria in the United States (2019–2032)

Table 5: Age-specific cases of Chronic Spontaneous Urticaria in the US (2019–2032)

Table 6: Prevalent cases of NCFB in EU-5 (2019–2032)

Table 7: Gender-specific Diagnosed Prevalence of NCFB in EU-5 (2019–2032)

Table 8: Etiology associated with NCFB in EU-5 (2019–2032)

Table 9: Total Prevalent cases of Chronic Spontaneous Urticaria in Japan (2019–2032)

Table 10: Gender-Specific cases of Chronic Spontaneous Urticaria in Japan (2019–2032)

Table 11: Age-specific cases of Chronic Spontaneous Urticaria in Japan (2019–2032)

Table 12: XOLAIR, Clinical Trial Description, 2022

Table 13: Ligelizumab, Clinical Trial Description, 2022

Table 14: LOU064, Clinical Trial Description, 2022

Table 15: Dupilumab, Clinical Trial Description, 2022

Table 16: Fenebrutinib, Clinical Trial Description, 2022

Table 17: Benralizumab, Clinical Trial Description, 2022

Table 18: KPL-716, Clinical Trial Description, 2022

Table 19: UB-221, Clinical Trial Description, 2022

Table 20: Mepolizumab, Clinical Trial Description, 2022

Table 21: AK002, Clinical Trial Description, 2022

Table 22: LY3454738, Clinical Trial Description, 2022

Table 23: Total Market Size of Chronic Spontaneous Urticaria in 7MM, USD Million (2019–2032)

Table 24: Total Market Size of Chronic Spontaneous Urticaria in the US, USD Million (2019–2032)

Table 25: Total Market Size of Chronic Spontaneous Urticaria by Therapies in the US, USD Million (2019–2032)

Table 26: Total Market Size of Chronic Spontaneous Urticaria  in  EU-5, USD Million (2019–2032)

Table 27: Market Size of Chronic Spontaneous Urticaria by Therapies in EU-5, USD Million (2019–2032)

Table 28: Total Market Size of Chronic Spontaneous Urticaria in the US, USD Million (2019–2032)

Table 29: Total Market Size of Chronic Spontaneous Urticaria by Therapies in Japan, USD Million (2019–2032)

List of Figures

Figure 1: Pathophysiology of Chronic Spontaneous Urticaria

Figure 2: Model of the mechanisms underlying Chronic Urticaria

Figure 3: Pathophysiology of Chronic Spontaneous Urticaria

Figure 4: Total Patient Population of Chronic Spontaneous Urticaria in 7MM (2019–2032)

Figure 5: Total Prevalent cases of Chronic Spontaneous Urticaria in United States (2019-2032)

Figure 6: Gender-specific Cases of Chronic Spontaneous Urticaria in the United States (2019–2032)

Figure 7: Age-specific cases of Chronic Spontaneous Urticaria in the United States (2019–2032)

Figure 8: Total Prevalent cases of Chronic Spontaneous Urticaria in EU-5 (2019–2032)

Figure 9: Total Prevalent cases of Chronic Spontaneous Urticaria in EU-5 (2019–2032)

Figure 10: Total Prevalent cases of Chronic Spontaneous Urticaria in EU-5 (2019–2032)

Figure 11: Total Prevalent cases of Chronic Spontaneous Urticaria in Japan (2019–2032)

Figure 12: Gender-Specific cases of Chronic Spontaneous Urticaria in Japan (2019–2032)

Figure 13: Age-specific cases of Chronic Spontaneous Urticaria in Japan (2019–2032)

Figure 14: Treatment Algorithm

Figure 15: Step-care approach to the treatment for Chronic Urticaria

Figure 16: Treatment Algorithm

Figure 17: Treatment Algorithm

Figure 18: Total Market Size of Chronic Spontaneous Urticaria in the 7MM, USD Million (2019–2032)

Figure 19: Total Market Size of CSU in the US, USD Million (2019–2032)

Figure 20: Total Market Size of CSU by Therapies in the US, USD Million (2019–2032)

Figure 21: Total Market Size of Chronic Spontaneous Urticaria in the EU-5, USD Million (2019–2032)

Figure 22: Market Size of Chronic Spontaneous Urticaria by Therapies in the EU-5, USD Million (2019–2032)

Figure 23: Total Market Size of CSU in Japan, USD Million (2019–2032)

Figure 24: Total Market Size of CSU by Therapies in Japan, USD Million (2019–2032)

Roche
Novartis
Sanofi Pharmaceutical
Genentech
AstraZeneca
Kiniksa Pharmaceuticals, Ltd
United BioPharma
GlaxoSmithKline
Allakos
Eli Lilly and Company

 

Forward to Friend

Need A Quote